Commentary on “The impact of intravesical gemcitabine and 1/3 dose bacillus Calmette-Guérin instillation therapy on the quality of life in patients with nonmuscle invasive bladder cancer: Results of a prospective, randomized, phase II trial.” Gontero P, Oderda M, Mehnert A, Gurioli A, Marson F, Lucca I, Rink M, Schmid M, Kluth LA, Pappagallo G, Sogni F, Sanguedolce F, Schiavina R, Martorana G, Shariat SF, Chun F.

Instillation Therapy ◽

Randomized Phase Ii ◽

The Impact ◽

The Impact of Intravesical Gemcitabine and 1/3 Dose Bacillus Calmette-Guérin Instillation Therapy on the Quality of Life in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Prospective, Randomized, Phase II Trial

The Journal of Urology ◽

10.1016/j.juro.2013.03.097 ◽

2013 ◽

Vol 190 (3) ◽

pp. 857-862 ◽

Cited By ~ 25

Author(s):

Paolo Gontero ◽

Marco Oderda ◽

Anja Mehnert ◽

Alberto Gurioli ◽

Francesco Marson ◽

...

Keyword(s):

Quality Of Life ◽

Bladder Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Instillation Therapy ◽

Randomized Phase Ii ◽

The Impact ◽

Randomized Controlled Study of the Efficacy, Safety and Quality of Life with Low Dose bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer

The Journal of Urology ◽

10.1016/j.juro.2015.08.075 ◽

2016 ◽

Vol 195 (1) ◽

pp. 41-46 ◽

Cited By ~ 26

Author(s):

Akira Yokomizo ◽

Yusuke Kanimoto ◽

Takehiko Okamura ◽

Seiichiro Ozono ◽

Hirofumi Koga ◽

...

Keyword(s):

Quality Of Life ◽

Bladder Cancer ◽

Low Dose ◽

Randomized Controlled Study ◽

Controlled Study ◽

Instillation Therapy ◽

Randomized Controlled ◽

A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity

Annals of Oncology ◽

10.1093/annonc/mdi047 ◽

2005 ◽

Vol 16 (2) ◽

pp. 282-288 ◽

Cited By ~ 83

Author(s):

M.M. Borner ◽

J. Bernhard ◽

D. Dietrich ◽

R. Popescu ◽

M. Wernli ◽

...

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Metastatic Colorectal Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Line Treatment ◽

First Line ◽

Randomized Phase Ii ◽

First Line Treatment

Longitudinal quality of life (QoL) study in a randomized phase II trial (FFCD 9803) assessing LV5FU2, LV5FU2-cisplatin or LV5FU2-irinotecan in patients (pts) with metastatic gastric adenocarcinoma (MGA)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.14_suppl.4150 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4150-4150 ◽

Cited By ~ 2

Author(s):

F. Bonnetain ◽

O. Bouche ◽

J.-L. Raoul ◽

M. Giovannini ◽

P.-L. Etienne ◽

...

Keyword(s):

Quality Of Life ◽

Gastric Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii

Longitudinal quality of life (QoL) study in a randomized phase II trial (FFCD 9803) assessing LV5FU2, LV5FU2-cisplatin or LV5FU2-irinotecan in patients (pts) with metastatic gastric adenocarcinoma (MGA)

Journal of Clinical Oncology ◽

10.1200/jco.2004.22.90140.4150 ◽

2004 ◽

Vol 22 (14_suppl) ◽

pp. 4150-4150

Author(s):

F. Bonnetain ◽

O. Bouche ◽

J.-L. Raoul ◽

M. Giovannini ◽

P.-L. Etienne ◽

...

Keyword(s):

Quality Of Life ◽

Gastric Adenocarcinoma ◽

Phase Ii ◽

Phase Ii Trial ◽

Randomized Phase Ii

Randomized Phase II Trial of Either Fluorouracil, Parenteral Hydroxyurea, Interferon-??t-2a, and Filgrastim or Doxorubicin/Docetaxel in Patients with Advanced Gastric Cancer with Quality-of-Life Assessment

The Cancer Journal ◽

10.1097/00130404-200205000-00013 ◽

2002 ◽

Vol 8 (3) ◽

pp. 282-286 ◽

Cited By ~ 16

Author(s):

Scott Wadler ◽

Carlos Brain ◽

Paul Catalano ◽

Avi I. Einzig ◽

David Cella ◽

...

Keyword(s):

Quality Of Life ◽

Gastric Cancer ◽

Advanced Gastric Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Life Assessment ◽

Quality Of Life Assessment ◽

Randomized Phase Ii

Late toxicity and quality of life from GETUG-AFU 22 study: A randomized phase II trial comparing 6 months of degarelix in combination with radiotherapy to radiotherapy alone for patients with detectable PSA after radical prostatectomy

European Urology Open Science ◽

10.1016/s2666-1683(20)33522-9 ◽

2020 ◽

Vol 19 ◽

pp. e1398-e1399

Author(s):

P. Sargos ◽

S. Guerif ◽

J. Fraisse ◽

E. Meyer ◽

S. Supiot ◽

...

Keyword(s):

Quality Of Life ◽

Radical Prostatectomy ◽

Phase Ii ◽

Phase Ii Trial ◽

Late Toxicity ◽

Randomized Phase Ii ◽

Radiotherapy Alone

80 Toxicity and Quality of Life Results from a Randomized Phase II Trial of HDR Monotherapy for Low and Intermediate-Risk Prostate Cancer

Radiotherapy and Oncology ◽

10.1016/s0167-8140(19)33371-7 ◽

2019 ◽

Vol 139 ◽

pp. S36

Author(s):

Yaser Hasan ◽

Andrew Loblaw ◽

Hans Chung ◽

Merrylee McGuffin ◽

Chia-Lin Tseng ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Intermediate Risk ◽

Randomized Phase Ii ◽

Risk Prostate Cancer

Toxicity and Quality of Life Results from a Randomized Phase II Trial of HDR Monotherapy for Low and Intermediate-Risk Prostate Cancer

Brachytherapy ◽

10.1016/j.brachy.2019.04.113 ◽

2019 ◽

Vol 18 (3) ◽

pp. S53-S54

Author(s):

Yaser Hasan ◽

Andrew Loblaw ◽

Hans Chung ◽

Merrylee McGuffin ◽

Chia-Lin Tseng ◽

...

Keyword(s):

Quality Of Life ◽

Prostate Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Intermediate Risk ◽

Randomized Phase Ii ◽

Risk Prostate Cancer

SWOG S0353: Phase II Trial of Intravesical Gemcitabine in Patients with Nonmuscle Invasive Bladder Cancer and Recurrence after 2 Prior Courses of Intravesical Bacillus Calmette-Guérin

The Journal of Urology ◽

10.1016/j.juro.2013.04.031 ◽

2013 ◽

Vol 190 (4) ◽

pp. 1200-1204 ◽

Cited By ~ 81

Author(s):

Eila C. Skinner ◽

Bryan Goldman ◽

Wael A. Sakr ◽

Daniel P. Petrylak ◽

Heinz-Josef Lenz ◽

...

Keyword(s):

Bladder Cancer ◽

Phase Ii ◽

Phase Ii Trial ◽

Invasive Bladder Cancer ◽